Format

Send to

Choose Destination
Oncoimmunology. 2014 Jan 1;3(1):e27817. Epub 2014 Jan 16.

Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy.

Author information

1
Drug Development Department (DITEP); Gustave Roussy; University Paris Sud; Villejuif, France.
2
Department of Medical Oncology; Gustave Roussy; University Paris Sud; Villejuif, France ; INSERM U981; Gustave Roussy; University Paris Sud; Villejuif, France.
3
SIRIC SOCRATE; Gustave Roussy; University Paris Sud; Villejuif, France.
4
Gustave Roussy; University Paris Sud; Villejuif, France.
5
Drug Development Department (DITEP); Gustave Roussy; University Paris Sud; Villejuif, France ; INSERM U981; Gustave Roussy; University Paris Sud; Villejuif, France ; SIRIC SOCRATE; Gustave Roussy; University Paris Sud; Villejuif, France ; Thoracic Multidisciplinary Committee; Gustave Roussy; University Paris Sud; Villejuif, France.

Abstract

Anti-PD-1/PD-L1 antibodies are emerging as promising anticancer therapeutics. Interestingly, elevated response rates to these agents are mostly documented among patients with tumors that bear high level of somatic mutations, like melanoma or non-small cell lung carcinoma. We herein formulate the hypothesis that high levels of mutational heterogeneity in the tumor could be the key for the success of immune checkpoint-targeting therapies.

KEYWORDS:

PD-1; PD-L1; immune checkpoints; immunotherapy; mutational heterogeneity

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center